Subgroup Identification and Individualized Treatment Policies: A Tutorial on the Hybrid Two-Stage Workflow

2025-12-31

AI Summary

This study addresses the heterogeneity of treatment effects in clinical research, where conventional subgroup analyses lack individual-level predictive power and purely machine learning–based approaches often lack statistical guarantees. To bridge this gap, the authors propose a two-stage hybrid workflow: first, using formal statistical hypothesis testing to confirm the presence of heterogeneous treatment effects, then constructing an individualized treatment strategy evaluated via cross-fitted doubly robust estimation under a Neyman–Pearson risk constraint. This framework integrates the interpretability of statistical inference with the predictive strength of machine learning, yielding a transparent, auditable, and statistically principled approach to heterogeneity. The method demonstrates efficacy in both simulation studies and the ACTG 175 HIV trial, and is accompanied by a practical implementation checklist along with guidance for alignment with regulatory-oriented heterogeneous treatment effect (HTE) assessment protocols.

Technology Category

• Machine Learning: Calibration & Uncertainty Quantification
• Humans and AI: Planning and Decision Support for Human-Machine Teams
• Search and Optimization: Mixed Discrete/Continuous Search

Application Category

• Responsible Web: Machine-in-the-loop, human agency and autonomy
• User Modeling, Personalization and Recommendation: Explainable and interpretable methods for personalization
• Web Mining and Content Analysis: Machine learning and data science for the Web

Abstract

Patients in clinical studies often exhibit heterogeneous treatment effect (HTE). Classical subgroup analyses provide inferential tools to test for effect modification, while modern machine learning methods estimate the Conditional Average Treatment Effect (CATE) to enable individual level prediction. Each paradigm has limitations: inference focused approaches may sacrifice predictive utility, and prediction focused approaches often lack statistical guarantees. We present a hybrid two-stage workflow that integrates these perspectives. Stage 1 applies statistical inference to test whether credible treatment effect heterogeneity exists with the protection against spurious findings. Stage 2 translates heterogeneity evidence into individualized treatment policies, evaluated by cross fitted doubly robust (DR) metrics with Neyman-Pearson (NP) constraints on harm. We illustrate the workflow with working examples based on simulated data and a real ACTG 175 HIV trial. This tutorial provides practical implementation checklists and discusses links to sponsor oriented HTE workflows, offering a transparent and auditable pathway from heterogeneity assessment to individualized treatment policies.

Problem

• heterogeneous treatment effect
• subgroup identification
• individualized treatment policies
• Conditional Average Treatment Effect
• statistical inference

Innovation

• heterogeneous treatment effect
• conditional average treatment effect
• doubly robust estimation
• individualized treatment policy
• two-stage workflow